Brissot Pierre, de Bels Frédéric
Service des Maladies du Foie, University Hospital Pontchaillou, Rennes, France.
Hematology Am Soc Hematol Educ Program. 2006:36-41. doi: 10.1182/asheducation-2006.1.36.
The term hemochromatosis encompasses at least four types of genetic iron overload conditions, most of them recently distinguished from one another as a result of the identification of a series of genes related to iron metabolism. At least three of these entities (HFE hemochromatosis, juvenile hemochromatosis and transferrin receptor 2 hemochromatosis) involve systemic hepcidin deficiency as a key pathogenetic factor. Major advances in the management of hemochromatosis influence the diagnostic approach to the disease, with the development of an overall non invasive strategy, mainly based on clinical, biological (iron parameters and genetic testing), and imaging (especially magnetic resonance imaging) data. Therapeutic management remains, on the curative side, dominated by phlebotomy (venesection), practical aspects of which have been recently revisited by the Guidelines Department of the French "Haute Autorité de Santé." However, innovative treatment approaches, based on the improved pathophysiological understanding of these diseases and the progress in iron chelation therapy, are emerging. Preventive therapy, focused on family screening, remains a key part of the management of hemochromatosis.
血色素沉着症这一术语涵盖至少四种遗传性铁过载病症,其中大多数最近因一系列与铁代谢相关基因的鉴定而相互区分开来。这些病症中至少有三种(HFE血色素沉着症、青少年血色素沉着症和转铁蛋白受体2血色素沉着症)涉及全身性铁调素缺乏,这是关键的致病因素。血色素沉着症管理方面的重大进展影响了该疾病的诊断方法,一种主要基于临床、生物学(铁参数和基因检测)以及影像学(尤其是磁共振成像)数据的全面非侵入性策略得以发展。在治疗方面,放血疗法(静脉切开术)仍然是主要的治疗手段,法国“最高卫生管理局”指南部门最近重新审视了其实际操作要点。然而,基于对这些疾病病理生理学认识的提高以及铁螯合疗法的进展,创新的治疗方法正在涌现。以家族筛查为重点的预防性治疗仍然是血色素沉着症管理的关键部分。